Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
Public ClinicalTrials.gov record NCT00077961. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Study of Rituximab Plus CAMPATH in Patients With Previously Treated Relapsed or Refractory Low-Grade Follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma
Study identification
- NCT ID
- NCT00077961
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Enrollment
- 49 participants
Conditions and interventions
Conditions
Interventions
- CAMPATH (alemtuzumab) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2003
- Primary completion
- Jan 31, 2006
- Completion
- Not listed
- Last update posted
- Mar 25, 2015
Started 2003
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Colorado Springs | Colorado | 80909 | — |
| Not listed | Ocala | Florida | 34474 | — |
| Not listed | Park Ridge | Illinois | 60068 | — |
| Not listed | Lafayette | Louisiana | 70506 | — |
| Not listed | New Orleans | Louisiana | 70115 | — |
| Not listed | Columbia | Missouri | 65201 | — |
| Not listed | Manhasset | New York | 11030 | — |
| Not listed | Cary | North Carolina | 27511 | — |
| Not listed | Canton | Ohio | 44718 | — |
| Not listed | Greenville | South Carolina | 29615 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00077961, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 25, 2015 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00077961 live on ClinicalTrials.gov.